season
influenza
epidem
period
pandem
import
caus
morbid
mortal
patient
chronic
comorbid
ill
extrem
age
pregnant
women
higher
risk
complic
requir
hospit
wherea
young
adult
obes
individu
also
increas
risk
pandem
sever
acut
respiratori
infect
avian
influenza
virus
pandem
potenti
continu
circul
wide
poultri
popul
infect
human
sporad
infect
caus
virus
may
result
sever
diseas
high
case
fatal
rate
human
background
immun
virus
sporad
human
case
due
avian
also
emerg
recent
year
global
circul
oseltamivirresist
season
influenza
emerg
viru
follow
continu
circul
rise
number
infect
human
ongo
spread
recent
month
poultri
popul
mani
countri
asia
africa
europ
middl
east
pandem
potenti
point
urgent
need
develop
effect
antivir
therapi
reduc
morbid
mortal
articl
review
epidemiolog
clinic
diagnost
treatment
aspect
import
emerg
influenza
virus
pose
threat
human
health
asiapacif
region
season
influenza
major
health
problem
instanc
hong
kong
influenza
b
account
respect
hospit
admiss
confirm
viral
infect
averag
annual
incid
hospit
laboratoryconfirm
influenza
infect
among
children
age
year
elderli
year
respect
furthermor
influenza
common
viru
detect
patient
die
respiratori
viral
infect
although
influenza
b
usual
associ
less
degre
diseas
burden
impact
human
health
substanti
previou
studi
conduct
hong
kong
reveal
laboratoryconfirm
influenzaassoci
hospit
admiss
due
influenza
b
much
higher
among
older
children
adolesc
age
year
observ
similar
data
europ
north
america
temper
region
influenza
exhibit
annual
season
peak
winter
howev
season
tropic
subtrop
region
variabl
instanc
hong
kong
subtrop
citi
time
influenza
exhibit
two
peak
januarymarch
juneaugust
occasion
two
peak
merg
without
obviou
gap
bimod
variabl
season
influenza
also
observ
countri
within
subtrop
tropic
region
pose
challeng
implement
annual
influenza
vaccin
campaign
well
question
whether
northern
southern
hemispher
version
influenza
vaccin
would
appropri
schemat
diagram
structur
influenza
virion
shown
figur
influenza
repres
one
exampl
virus
segment
genom
togeth
widespread
infect
differ
subtyp
variou
anim
speci
allow
robust
evolut
process
reassort
prerequisit
reassort
simultan
infect
one
strain
virus
host
refer
mix
vessel
allow
replic
swab
gene
segment
differ
strain
virus
water
bird
wellknown
mix
vessel
reassort
like
tropism
restrict
avian
speci
new
reassort
may
pose
problem
land
bird
poultri
subsequ
human
concern
swine
anoth
wellknown
mix
vessel
uniqu
properti
swine
suscept
avian
human
influenza
virus
thu
reassort
swine
like
gain
tropism
infect
human
field
observ
made
earli
point
influenza
outbreak
began
either
pig
peopl
rapidli
transfer
swine
like
play
role
mix
vessel
creat
pandem
strain
although
pandem
strain
probabl
entir
avianlik
viru
pandem
strain
reassort
humanand
avianorigin
virus
recent
pandem
sever
occur
guarante
next
pandem
mild
present
subtyp
particular
concern
crossspeci
infect
especi
recent
strong
wave
human
infect
mainland
china
underscor
next
pandem
could
immin
countri
pandem
prepared
place
includ
antivir
stockpil
pandem
vaccin
prepar
would
better
achiev
joint
multigovern
industri
partnership
human
case
highli
pathogen
avian
influenza
first
detect
hong
kong
number
affect
countri
increas
expans
east
southeast
asia
west
asia
africa
sharp
rise
egypt
sinc
novemb
march
death
human
case
countri
sinc
canadian
tourist
die
relat
meningoenceph
alberta
januari
visit
beij
decemb
without
obviou
exposur
infect
avian
sourc
environment
contamin
histori
exposur
dead
sick
poultrywild
bird
occur
case
human
infect
incub
period
infect
rang
day
may
long
day
clinic
spectrum
may
rang
asymptomat
infect
mild
influenzalik
ill
sever
pneumonia
multiorgan
failur
human
case
link
consumpt
dish
made
raw
contamin
poultri
blood
howev
slaughter
defeath
handl
carcass
infect
poultri
prepar
poultri
consumpt
especi
household
set
appear
import
risk
factor
among
fatal
case
median
durat
symptom
onset
death
day
rang
day
viral
rna
present
blood
fatal
case
associ
higher
pharyng
viral
load
nasopharyng
swab
sampl
bronchoalveolar
lavag
cerebrospin
fluid
sampl
posit
canadian
case
influenza
viru
variou
molecular
test
method
includ
sequenc
addit
lymphopenia
high
chemokinecytokin
level
observ
sever
infect
correl
pharyng
load
new
reassort
genotyp
contain
haemagglutinin
ha
neuraminidas
na
gene
clade
intern
gene
clade
detect
associ
highest
number
case
n
death
n
cambodia
complet
viral
genom
analysi
fatal
case
canada
shown
ha
gene
clade
reassort
subtyp
lineag
polymeras
basic
gene
without
mutat
confer
resist
adamantan
na
inhibitor
nai
humanhuman
transmiss
remain
rare
metaanalysi
shown
studi
particip
studi
expos
patient
infect
serolog
evid
prior
infect
delay
deliveri
appropri
treatment
patient
influenza
infect
indonesia
mainli
relat
delay
diagnosi
rather
late
present
healthcar
set
age
countri
per
capita
govern
health
expenditur
delay
symptom
onset
hospit
risk
factor
mortal
relat
infect
emphas
import
earli
diagnosi
treatment
support
care
systemat
review
shown
femal
higher
risk
death
ci
follow
infect
wherea
young
age
particular
year
protect
ci
human
infect
novel
avian
influenza
viru
first
report
china
march
patient
hospit
sever
pneumonia
five
season
epidem
china
sinc
viru
first
discov
estim
risk
death
hospit
fatal
risk
hfr
among
hospit
case
infect
second
epidem
credibl
interv
slightli
higher
correspond
risk
first
wave
second
epidem
hfr
estim
ci
patient
age
year
ci
among
age
year
upsurg
human
infect
observ
sinc
novemb
mainland
china
fifth
epidem
wave
number
human
case
higher
previou
two
wave
major
recent
report
human
case
associ
exposur
infect
live
poultri
contamin
environ
includ
wet
market
live
poultri
sold
addit
human
case
geograph
widespread
case
also
report
rural
area
unlik
previou
epidem
fig
phylogenet
analysi
ha
gene
isol
collect
human
suggest
viru
evolv
recent
isol
cluster
separ
branch
supplementari
figur
april
laboratoryconfirm
case
human
infect
avian
influenza
viru
report
world
health
organ
human
case
infect
export
mainland
china
confirm
hong
kong
n
taiwan
n
macau
n
canada
n
malaysia
n
visitor
develop
ill
return
mainland
china
home
citi
incub
period
human
infect
viru
rang
day
averag
day
median
time
poultri
exposur
diseas
onset
day
wherea
median
time
ill
onset
hospit
acut
respiratori
distress
syndrom
ard
develop
antivir
therapi
death
day
respect
preexist
comorbid
condit
occur
case
promin
clinic
featur
admiss
sever
influenza
syndrom
fever
cough
fatigu
dyspnoea
wherea
strike
laboratori
find
mark
lymphopenia
thrombocytopenia
elev
cytokin
level
observ
patient
excess
cytokin
respons
may
contribut
clinic
sever
infect
limit
human
human
transmiss
least
two
epidemiolog
link
case
due
close
household
contact
index
patient
report
number
famili
cluster
infect
nosocomi
transmiss
infect
two
patient
share
hospit
room
cotransmiss
avian
influenza
virus
two
patient
haematolog
disord
share
room
bed
distanc
report
comparison
clinic
featur
human
case
shown
tabl
closur
live
poultri
market
lpm
mainland
china
tremend
reduc
risk
infect
temporarili
closur
difficult
sustain
due
cultur
prefer
live
poultri
ecolog
model
studi
estim
closur
lpm
reduc
mean
daili
number
viru
infect
four
affect
citi
retrospect
serolog
studi
blood
specimen
taken
januarymay
octobernovemb
subject
work
lpm
farm
slaughter
hous
kept
backyard
poultri
eastern
china
epidem
occur
reveal
evid
infect
novel
avian
influenza
subtyp
first
human
case
avian
infect
report
femal
pneumonia
taiwan
may
subsequ
full
recoveri
follow
treatment
oseltamivir
first
human
case
avian
confirm
male
sichuan
provinc
onset
ill
death
median
day
case
fatal
rate
hospit
china
may
fatal
outcom
second
case
confirm
male
histori
exposur
live
poultri
guangdong
provinc
decemb
viru
reassort
contain
seven
gene
na
gene
viru
circul
duck
fig
latest
case
report
decemb
addit
china
confirm
three
human
infect
two
fatal
avian
virus
contain
intern
gene
similar
viru
virus
low
pathogen
poultri
therefor
difficult
detect
bird
contrast
highli
pathogen
viru
highli
pathogen
avian
influenza
virus
belong
clade
agooseguangdong
lineag
detect
wild
bird
poultri
china
japan
south
korea
netherland
germani
itali
russia
uk
northern
ireland
viru
detect
sporad
canada
usa
wild
bird
poultri
virus
also
detect
taiwan
china
hungari
sweden
sinc
june
mani
countri
europ
asia
detect
infect
wild
bird
andor
domest
poultri
mani
recent
detect
associ
mortal
wild
bird
although
human
infect
detect
ongo
spread
viru
differ
countri
recent
month
worrisom
may
increas
risk
human
infect
visitor
return
area
affect
avian
influenza
develop
respiratori
symptom
fever
within
day
return
enquir
relev
histori
travel
histori
occup
contact
histori
cluster
facilit
earli
diagnosi
treatment
import
obtain
histori
contact
poultri
live
sickdead
poultri
viru
may
caus
mild
symptom
poultri
contrast
exposur
wet
market
known
avian
influenza
case
laboratori
exposur
includ
staff
handl
spillag
patient
influenzalik
ill
present
dyspnoea
tachypnoea
evid
hypoxaemia
pulmonari
infiltr
chest
radiograph
hospit
earli
case
identif
isol
precaut
would
facilit
clinic
manag
may
reduc
risk
sever
infect
relat
complic
season
epidem
zoonot
pandem
influenza
addit
reduc
risk
influenza
transmiss
mitig
impact
outbreak
healthcar
system
common
find
sever
influenza
infect
includ
low
normal
white
cell
count
lymphopenia
thrombocytopenia
increas
serum
transaminas
lactat
dehydrogenas
ldh
creatin
kinas
ureacreatinin
influenza
clinic
inform
network
flucin
studi
earli
elev
creactiv
protein
mgl
independ
predictor
sever
outcom
studi
patient
hospit
communityacquir
pneumonia
cap
procalcitonin
concentr
strong
associ
need
invas
mechan
ventil
imv
inotrop
support
studi
higher
level
certain
biomark
present
link
inflamm
coagul
immun
function
interleukin
cluster
differenti
interferon
gammainduc
protein
lipopolysaccharid
bind
protein
lbp
monocyt
chemoattract
interferon
gammainduc
protein
associ
diseas
progress
outpati
hospit
influenza
laboratori
diagnosi
play
import
role
manag
influenza
narrow
window
effect
antivir
intervent
season
avian
influenza
demand
rapid
turnaround
time
nowaday
laboratori
employ
either
real
time
revers
transcript
polymeras
chain
reaction
rrtpcr
base
method
antigen
detectionbas
assay
rrtpcr
approach
sensit
appli
wide
varieti
specimen
includ
less
invas
throat
swab
sampl
requir
certain
degre
laboratori
setup
technic
skill
readili
avail
mani
healthcar
set
antigenbas
rapid
influenza
diagnost
test
ridt
although
less
sensit
still
test
choic
particularli
pointofcar
test
experi
ridt
suggest
sensit
could
lower
patient
present
day
onset
ill
young
children
compar
elderli
case
pneumonia
compar
without
therefor
crucial
evalu
perform
respect
set
ridt
appli
specimen
choic
critic
situat
nasopharyng
aspirateswab
prefer
choic
specimen
season
influenza
falseneg
result
may
occur
patient
sever
pneumonia
viral
load
remain
high
lower
respiratori
tract
lrt
becom
undetect
upper
respiratori
tract
urt
similarli
lrt
specimen
tracheal
aspir
sputum
specimen
choic
diagnosi
avian
influenza
infect
human
viral
load
urt
typic
low
develop
avail
afford
reliabl
molecular
diagnost
test
includ
multiplex
pcr
would
facilit
futur
clinic
manag
patient
sever
cap
due
viral
bacteri
aetiolog
advantag
limit
differ
diagnost
test
influenza
summar
tabl
inhibitor
amantadin
rimantadin
nai
oseltamivir
peramivir
zanamivir
laninamivir
main
antivir
agent
approv
prevent
treatment
influenza
gener
antivir
treatment
commenc
soon
possibl
patient
hospit
confirm
suspect
influenza
sever
complic
progress
ill
also
outpati
higher
risk
influenza
complic
inhibitor
adamantan
effect
influenza
b
virus
recent
circul
influenza
influenza
virus
resist
due
mutat
ion
channel
howev
avian
influenza
strain
still
suscept
combin
adamantan
nai
may
enhanc
antivir
activ
suscept
isol
oseltamivir
effect
reduc
mortal
p
influenza
infect
given
onset
respiratori
failur
may
provid
surviv
benefit
reduct
mortal
treatment
start
within
day
symptom
onset
sever
observ
studi
shown
treatment
oseltamivir
adult
hospit
sever
influenza
associ
lower
mortal
better
clinic
outcom
especi
antivir
treatment
initi
within
day
ill
onset
even
late
day
symptom
onset
systemat
review
shown
prophylact
studi
oseltamivir
could
reduc
proport
symptomat
influenza
wherea
treatment
studi
modestli
reduc
time
first
allevi
symptom
h
caus
nausea
vomit
headach
renalpsychiatr
side
effect
metaanalysi
random
control
trial
rct
shown
oseltamivir
adult
influenza
shorten
time
clinic
symptom
allevi
reduc
risk
lrt
complic
hospit
increas
occurr
nausea
vomit
oseltamivir
resist
infrequ
circul
b
virus
import
monitor
antivir
resist
manag
patient
sever
influenza
virus
amantadin
resist
due
substitut
ion
channel
protein
patient
hospit
sever
infect
reduct
viral
load
follow
oseltamivir
treatment
associ
improv
outcom
wherea
emerg
viru
resist
nai
harbour
mutat
associ
poor
outcom
lack
respons
oseltamivir
peramivir
reduc
suscept
zanamivir
laninamivir
rise
inhibitori
concentr
ic
respect
two
patient
sever
infect
mutat
requir
extracorpor
membran
oxygen
receiv
system
corticosteroid
treatment
might
contribut
treatment
failur
fatal
outcom
recommend
treatment
durat
oseltamivir
gener
day
longer
treatment
day
guid
clinic
virolog
test
recommend
advis
critic
ill
patient
respiratori
failur
persist
viral
replic
lrt
whether
higher
standard
dose
nai
would
provid
greater
antivir
effect
patient
requir
investig
one
rct
hospit
patient
children
reveal
clinic
virolog
advantag
compar
doubl
dose
oseltamivir
standard
dose
addit
benefit
higher
dose
oseltamivir
treatment
observ
adult
hospit
influenza
although
faster
virolog
respons
note
influenza
b
howev
rct
critic
ill
patient
canada
found
therapi
tripl
dose
oseltamivir
associ
higher
proport
viral
clearanc
day
standard
therapi
vs
p
intraven
iv
peramivir
treatment
associ
viral
rna
declin
well
cultur
rna
neg
occur
similar
rate
oral
oseltamivir
day
among
adult
patient
hospit
influenzaassoci
lrt
complic
variou
nai
dosag
adult
adjust
renal
failur
shown
tabl
zanamivir
laninamivir
quit
similar
profil
drug
suscept
one
exampl
mutat
confer
high
level
resist
oseltamivir
carboxyl
reduc
suscept
peramivir
virus
reduc
suscept
zanamivir
laninamivir
ridt
chromatograph
immunoassay
fluorescencebas
immunoassay
applic
np
swab
nasal
andor
throat
swab
np
aspirateswash
train
protect
equip
requir
perform
best
appli
within
h
onset
signific
drop
viral
load
day
select
popul
lower
sensit
viru
report
viral
cell
cultur
detect
viabl
virus
includ
contain
liveattenu
influenza
vaccin
laiv
isol
subject
phenotyp
resist
assay
eg
neuraminidas
enzym
inhibit
assay
viral
load
specimen
qualiti
transport
storag
process
techniqu
may
affect
test
perform
pcr
assay
either
provid
univers
detect
influenza
viru
target
matrix
gene
subtypespecif
viru
detect
eg
target
haemagglutinin
ha
gene
virus
subtyp
may
indic
novel
strain
newer
molecularbas
pointofcar
test
may
improv
access
reduc
process
time
technic
demand
may
allow
detect
multipl
virus
costeffect
pcr
variabl
depend
circumst
multiplex
pcr
platform
may
provid
detect
respiratori
virus
eg
rsv
human
metapneumoviru
parainfluenza
viru
rhinoviru
coronaviru
atyp
pathogen
eg
mycoplasma
pneumonia
chlamydophila
pneumonia
dfa
direct
fluoresc
antibodi
test
ifa
immunofluoresc
assay
np
nasopharyng
ridt
rapid
influenza
diagnost
test
rsv
respiratori
syncyti
viru
significantli
intraven
zanamivir
use
wide
compassion
ground
late
treatment
critic
ill
adult
influenza
suspect
proven
oseltamivir
resist
drugrel
trend
safeti
paramet
subset
patient
posit
pcr
test
baselin
influenza
show
median
decreas
nasopharyng
viral
rna
load
log
copiesml
day
treatment
intraven
zanamivir
use
favour
outcom
patient
sever
infect
complic
pneumonia
respond
oseltamivir
initi
favipiravir
inhibitor
viral
rnadepend
rna
polymeras
strong
antivir
activ
nairesist
sensit
influenza
virus
system
corticosteroid
immunomodul
agent
sever
influenza
system
corticosteroid
use
frequent
treatment
influenzarel
ard
howev
metaanalysi
data
predominantli
relat
treatment
sever
influenza
shown
system
corticosteroid
associ
increas
mortal
ci
pool
subgroup
analysi
adjust
estim
mortal
four
studi
found
ci
comparison
control
highdos
corticosteroid
mgday
methylprednisolon
eqv
associ
increas
risk
mortal
vs
p
mortal
vs
p
longer
viral
shed
day
vs
day
p
patient
influenza
viral
pneumonia
differ
low
dose
mgday
methylprednisolon
control
studi
adult
hospit
influenza
hong
kong
singapor
beij
receiv
system
corticosteroid
bacteri
superinfect
increas
risk
death
adjust
hazard
ratio
hr
ci
system
corticosteroid
increas
risk
superinfect
death
control
indic
adjust
hr
ci
among
adult
sever
sepsi
septic
shock
use
lowdos
hydrocortison
versu
placebo
reduc
risk
septic
shock
within
day
find
support
use
hydrocortison
patient
without
septic
shock
role
lowdos
system
corticosteroid
need
investig
properli
plan
rct
studi
critic
ill
patient
infect
influenza
pdm
requir
imv
addit
mammalian
target
rapamycin
inhibitor
sirolimu
mgday
day
oseltamivir
prednisolon
n
associ
higher
frequenc
liber
imv
vs
p
shorter
durat
imv
day
vs
day
p
higher
chanc
achiev
lrt
viral
rna
neg
day
vs
p
without
addit
sirolimu
n
role
sirolimu
plu
oseltamivir
versu
oseltamivir
alon
larger
sampl
size
examin
without
system
corticosteroid
recent
studi
adult
hospit
shown
tripl
combin
treatment
day
clarithromycin
mg
naproxen
mg
oseltamivir
mg
twice
daili
bd
follow
day
oseltamivir
reduc
mortal
length
hospit
stay
versu
oseltamivir
mg
bd
without
placebo
day
control
confirmatori
studi
role
tripl
combin
would
interest
exploratori
post
hoc
metaanalysi
studi
sever
acut
respiratori
syndrom
sar
sever
influenza
show
signific
reduct
pool
odd
mortal
follow
convalesc
plasma
versu
placebo
treatment
ci
thu
convalesc
plasma
hyperimmun
globulin
may
nosocomi
opportunist
airborn
transmiss
implic
medic
ward
imbalanc
airflow
use
noninvas
ventil
niv
index
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
copd
standard
contact
droplet
precaut
recommend
routin
manag
patient
hospit
influenza
main
infect
prevent
control
measur
manag
influenza
droplet
precaut
wear
surgic
mask
within
patient
contact
precaut
wear
gown
glove
enter
room
remov
leav
droplet
precaut
ad
standard
precaut
provid
care
patient
symptom
acut
respiratori
infect
contact
precaut
eye
protect
ad
care
probabl
confirm
case
avian
influenza
infect
tabl
studi
measur
amount
influenza
rna
aerosol
vicin
patient
undergo
aerosolgener
procedur
agp
shown
bronchoscopi
respiratoryairway
suction
definit
procedur
produc
aerosol
background
baselin
valu
thu
import
healthcar
worker
take
airborn
precaut
perform
agp
prefer
isol
room
neg
pressur
order
reduc
room
contamin
hospit
set
major
health
organ
recommend
applic
minimum
room
ventil
rate
air
chang
per
hour
ach
exist
facil
wherea
higher
ventil
ach
recommend
new
renov
construct
especi
care
patient
receiv
mechan
ventil
agp
singl
circuit
niv
may
lead
room
contamin
exhal
aerosol
recommend
appli
niv
via
helmet
doubl
circuit
tube
patient
mild
moder
respiratori
failur
influenza
pandem
howev
import
ensur
good
seal
neckhelmet
interfac
prevent
nosocomi
transmiss
environment
contamin
exhal
aerosol
postexposur
prophylaxi
daili
dose
nai
eg
oseltamivir
mg
daili
adult
day
recommend
unprotect
close
contact
patient
season
influenza
risk
complic
influenza
recommend
routin
postexposur
antivir
chemoprophylaxi
viru
howev
asymptomat
person
substanti
unprotect
prolong
exposur
ill
patient
infect
occur
initi
empir
postexposur
antivir
treatment
eg
oseltamivir
mg
oral
bd
day
presumpt
influenza
viru
infect
occur
may
consid
like
limit
healthcar
set
involv
substanti
exposur
higher
risk
complic
tabl
infect
prevent
control
measur
assess
patient
complic
influenza
clinician
pay
attent
case
communityacquir
pneumonia
patient
travel
histori
earli
case
detect
clinician
remain
vigil
avian
influenza
elicit
relev
clinic
epidemiolog
inform
patient
fever
travel
histori
occup
contact
histori
cluster
standard
contact
droplet
precaut
recommend
routin
manag
patient
hospit
influenza
droplet
precaut
wear
surgic
mask
within
patient
contact
precaut
wear
gown
glove
enter
room
remov
leav
provid
care
patient
symptom
acut
respiratori
infect
contact
precaut
eye
protect
ad
care
probabl
confirm
case
avian
influenza
infect
risk
assess
conduct
perform
agp
case
sever
influenza
advis
perform
agp
airborn
isol
room
airborn
isol
room
avail
follow
minimum
hourli
averag
ventil
rate
provid
natur
ventil
lspatient
hourli
averag
ventil
rate
airborn
precaut
room
minimum
lspatient
note
appli
new
healthcar
facil
major
renov
b
lspatient
gener
ward
outpati
depart
c
lsm
corridor
transient
space
without
fix
number
patient
view
increas
influenza
activ
winter
season
emerg
threat
avian
influenza
healthcar
worker
visitor
recommend
wear
surgic
mask
enter
patient
care
area
strengthen
hand
hygien
agp
aerosolgener
procedur
influenza
viru
infect
includ
patient
sever
immunosuppress
neonat
infant
pregnant
earli
postpartum
women
elderli
adult
person
comorbid
highli
vulner
patient
unprotect
healthcar
worker
especi
involv
agp
annual
season
influenza
vaccin
recommend
highrisk
group
includ
resid
institut
elderli
disabl
age
chronic
ill
age
year
month
year
poultri
worker
countri
affect
avian
influenza
healthcar
worker
especi
frequent
contact
highrisk
person
household
contact
highrisk
person
vaccin
rate
among
healthcar
worker
highli
variabl
differ
countri
conclus
evid
season
influenza
vaccin
healthcar
worker
may
protect
patient
term
reduct
risk
mortal
influenzalik
ill
survey
hong
kong
assess
accept
addit
ad
hoc
influenza
vaccin
among
healthcar
profession
follow
season
signific
antigen
drift
shown
strongest
factor
associ
accept
addit
influenza
vaccin
includ
immun
influenza
vaccin
past
year
higher
perceiv
risk
contract
influenza
higher
perceiv
sever
diseas
impact
current
influenza
vaccin
induc
strainspecif
immun
ideal
rapidli
mutat
viru
univers
influenza
vaccin
capabl
induc
broad
crossprotect
across
strain
need
end
antigen
linear
peptid
conserv
across
influenza
strain
evalu
vaccin
target
approach
prepar
viruslikeparticl
base
ha
na
protein
viruslik
particl
cocktail
season
potenti
pandem
strain
prepar
demonstr
promis
result
endem
half
provinc
mainland
china
continu
caus
recurr
zoonot
diseas
winter
month
public
health
measur
control
sourc
rest
day
everi
month
poultri
worker
thoroughli
clean
lpm
environ
ban
stock
live
poultri
market
overnight
import
separ
live
duck
gees
landbas
ie
nonaquat
poultri
lpm
system
reduc
risk
emerg
zoonot
epizoot
virus
sourc
long
run
advis
adopt
complet
transit
sale
live
poultri
wholesal
retail
lpm
central
slaughter
sale
chill
frozen
poultri
season
influenza
epidem
period
pandem
import
caus
morbid
mortal
apart
influenza
viru
sporad
human
case
infect
infect
due
viru
especi
recent
upsurg
number
human
infect
mainland
china
great
concern
widespread
poultri
outbreak
due
mani
countri
increas
risk
human
infect
earli
isol
treatment
nai
adult
hospit
sever
influenza
associ
lower
mortal
better
clinic
outcom
whether
higher
standard
dose
nai
may
provid
greater
antivir
effect
patient
would
requir
investig
highdos
system
corticosteroid
associ
wors
outcom
patient
sever
influenza
complic
ard
urgent
need
develop
effect
antivir
therapi
treatment
influenza
infect
univers
hong
kong
professor
pksc
renown
clinic
virologist
special
interest
tumour
virolog
human
respiratori
virus
publish
scientif
paper
attain
hindex
nl
professor
infecti
diseas
chines
univers
hong
kong
main
research
interest
includ
respiratori
viral
infect
influenza
rsv
coronaviru
cap
focus
clinic
trial
patient
outcom
virokinet
host
respons
infect
control
hospit
set
current
work
novel
antivir
adjunct
therapi
sever
diseas
